$A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors$

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors

Abstract Background Several programmed cell death ligand 1 (PD‐L1)/programmed cell death protein 1 (PD‐1) antibodies have been approved for cancer treatment worldwide. Their pharmacokinetic and pharmacodynamic characteristics have been reported mainly in western countries, but related data in Chines...

Full description

Bibliographic Details
Main Authors:	Xiao‐Li Wei, Chao Ren, Feng‐Hua Wang, Yang Zhang, Hong‐Yun Zhao, Ben‐Yan Zou, Zhi‐Qiang Wang, Miao‐Zhen Qiu, Dong‐Sheng Zhang, Hui‐Yan Luo, Feng Wang, Sheng Yao, Rui‐Hua Xu
Format:	Article
Language:	English
Published:	Wiley 2020-08-01
Series:	Cancer Communications
Subjects:	anti‐PD‐1 antibody toripalimab phase I study safety efficacy pharmacokinetics
Online Access:	https://doi.org/10.1002/cac2.12068

Similar Items

Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report
by: Yuqing Bu, et al.
Published: (2023-03-01)

Effectiveness and Safety of Toripalimab Combination Therapies for Patients With Chemo-Resistant Choriocarcinoma
by: Xiaomei Liu, et al.
Published: (2022-04-01)

Flat dose regimen of toripalimab based on model-informed drug development approach
by: Lili Li, et al.
Published: (2023-01-01)

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
by: Lin Zhang, et al.
Published: (2022-01-01)

Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial
by: Zhenyu Wen, et al.
Published: (2023-10-01)

Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab
by: Huanyu Zhou, et al.
Published: (2022-03-01)

Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis
by: Feng Wang, et al.
Published: (2021-09-01)

Cost-effectiveness analysis of toripalimab for metastatic or recurrent triple-negative breast cancer
by: Jiangbo Shao, et al.
Published: (2024-01-01)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
by: Ze-Rui Zhao, et al.
Published: (2021-01-01)

Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial
by: Jie Chen, et al.
Published: (2022-07-01)

Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer
by: He C, et al.
Published: (2021-09-01)

Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
by: Gengwei Huo, et al.
Published: (2023-02-01)

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study
by: Wenqun Xing, et al.
Published: (2021-12-01)

Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China
by: Mengdie Zhang, et al.
Published: (2023-05-01)

Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer
by: Hao Wang, et al.
Published: (2023-03-01)

Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
by: Ye Tao, et al.
Published: (2023-05-01)

A Dramatic Response to Toripalimab With Chemotherapy and Antiangiogenic Agent Followed by Surgery in a Stage IIIB Lung Adenocarcinoma Patient With an Uncommon EGFR Mutation: A Case Report
by: Pengda Zhai, et al.
Published: (2022-07-01)

Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
by: Ning Zan, et al.
Published: (2022-02-01)

Case Report: Toripalimab: a novel immune checkpoint inhibitor in advanced nasopharyngeal carcinoma and severe immune-related colitis
by: Canhua Luo, et al.
Published: (2023-11-01)

Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report
by: Jianping He, et al.
Published: (2023-03-01)

Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy
by: Yong Li, et al.
Published: (2022-05-01)

Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study
by: Yongbiao Chen, et al.
Published: (2023-03-01)

A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)Research in context
by: Rui Chen, et al.
Published: (2023-08-01)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020-06-01)

Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective
by: Kexun Zhou, et al.
Published: (2023-05-01)

Evaluation of 124I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice
by: Haifeng Huang, et al.
Published: (2020-07-01)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
by: Miao Wang, et al.
Published: (2021-12-01)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
by: Yuqian Feng, et al.
Published: (2021-02-01)

Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage
by: Shan Su, et al.
Published: (2021-12-01)

Stevens–Johnson syndrome induced by toripalimab in a previously EGFR-TKI-treated advanced lung adenocarcinoma patient harboring EGFR mutations 19 del/T790M/C797S in trans and cis: a case report
by: Yang Chen, et al.
Published: (2023-11-01)

Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies
by: Chenxi Sun, et al.
Published: (2023-12-01)

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
by: Yi Que, et al.
Published: (2021-07-01)

Clinical Analysis of Docetaxel Combined with PD-1/PD-L1 Inhibitor in Second-line Treatment of Advanced Non-small Cell Lung Cancer
by: Qing CHEN, et al.
Published: (2021-09-01)

Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
by: Sho Yoshimoto, et al.
Published: (2023-12-01)

A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs
by: Aman P. Singh, et al.
Published: (2019-02-01)

Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study
by: Bai H, et al.
Published: (2024-02-01)

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC
by: Yunchao Wang, et al.
Published: (2023-01-01)

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
by: Meng‐Meng Teng, et al.
Published: (2021-09-01)

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
by: Liping Pei, et al.
Published: (2023-02-01)

Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis
by: Youwen Zhu, et al.
Published: (2022-05-01)